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ABSTRACT
We have performed a phase I dose escalation of 4-Hydroperoxycyclophosphamide (4HC) purging of autologous
peripheral blood progenitor cells (PBPCs) to improve the outcome of autologous transplantation for patients with
myeloid leukemia. Peripheral blood stem cells were mobilized after cytosine arabinoside of 2 g/m2 every 12 hours 
8 doses with etoposide of 40 mg/kg total dose infused over 4 days, followed by growth factor support. The preparative
regimen included Busulfan of 1 mg/kg orally every 6 hours  16 doses, followed by etoposide of 60 mg/kg  1 day
(the patient with chronic myeloid leukemia received cyclophosphamide of 60 mg/kg/d  2 days in lieu of etoposide).
PBPCs purged with 4HC were infused following this induction. Toxicities included grade 3 or 4 skin rashes,
stomatitis/mucositis, and delay in time to hematopoietic recovery. The maximum tolerated dose of 4HC used to
purge PBPCs in this trial was 20 g/mL, which resulted in an average of 18 days for white blood cells and 28 days
for platelet recovery. With a median follow-up of 2.25 years in surviving patients, the 3-year disease free survival rate
is 44% and the overall survival rate is 89%. These data suggest that autologous PBPCs are more sensitive than
marrow purged with 4HC, tolerating less intense purging, although a survival advantage may still be seen and should
be assessed in larger studies. Approaches to minimize stomatitis and protect normal stem cells from the toxicity of
4HC may improve the tolerance and efficacy of this approach.
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INTRODUCTION
It is estimated that in the United States alone, there will be
approximately 10, 600 new cases of acute myeloid leukemia
(AML) diagnosed in the upcoming year, with the average age at
diagnosis of 65 years. AML is responsible for approximately
7,400 deaths a year, accounting for 1% of all cancer deaths in the
United States [1].
For those patients who relapse after initial response to
chemotherapy, autologous bone marrow transplantation
(ABMT) is often used in an attempt to prolong remission.
However, many patients treated with ABMT relapse, in part
because of residual disease in the graft [2,3]. As a typical graft
obtained from a patient in complete remission prior to postin-
duction therapy may show up to 10e10 leukemia cells [4], purg-
ing remains an attractive area of pursuit to improve outcomes.
4-Hydroperoxycyclophosphamide (4HC), the active form of cy-
clophosphamide, has been shown to be very toxic to leukemiac
cells and has been used to purge stem cells derived from marrow
in prior studies [5,6]. Although 4HC is toxic to stem cells and
leukemic cells alike, it is shown that leukemic progenitors are
more susceptible to the cytotoxic effect than normal marrow
stem cells [7]. Furthermore, studies conducted on purged bone
marrow at Johns Hopkins University show an increase in
long-term remission rates. Patients treated with 4HC had an
adjusted 3-year probability of leukemia-free survival for pa-
tients in ﬁrst remission of 56% (47% to 64%) and in second
or greater remission of 31% (95% conﬁdence interval [CI]:
18% to 45%) [6].
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Although 4HC has been shown to be an effective marrow
purging agent, it is also associated with a signiﬁcantly delayed
hematopoietic recovery [5,8]. One may try to overcome this
complication with the use of peripheral blood progenitor cells
(PBPCs), which have been shown to provide a more rapid
hematopoietic recovery following high-dose therapy than un-
mobilized bone marrow grafts [9]. This study is a phase I, dose
escalation study of 4HC with data on toxicity and time of
recovery presented to estimate the maximum tolerated dose
(MTD) of 4HC that can be used to purge PBPCs in patients in
second remission from leukemia undergoing high-dose therapy.
MATERIALS AND METHODS
Patient Eligibility
Patients older than 18 years of age who were in second
remission AML for at least 4 weeks prior to entry or who had
chronic myeloid leukemia (CML) in chronic phase were eligible
to participate in the study. Only patients with Karnofsky
scores  70% at study entry and life expectancies of longer than
8 weeks were considered. All patients tested had counts of
absolute neutrophil count (ANC) 1000/L, platelets
80,000/L, creatinine 2.0 mg/dL, bilirubin 2.0 mg/dL,
aspartate aminotransferase 2 times the upper limit of normal,
and were human immunodeﬁciecy virus–negative. Prior to
transplantation, pulmonary and cardiac function had to reveal a
diffuse capacity of the lung of 50% of the predicted value and
an ejection fraction of 50%. Female patients were required to
have a current negative pregnancy test if of child-bearing po-
tential and were required to not be lactating during the course of
the trial. All eligible patients who were to undergo autologous
therapy for second remission AML were offered this protocol.
The Duke Institutional Review Board approved the protocol,
and all patients provided written informed consent.
Mobilization, Pheresis, and Purging
To mobilize PBPCs, patients were hydrated and treated
with cytosine arabinoside of 2 g/m2 over 2 hours every 12 hours
for 8 total doses and etoposide of 40 mg/kg total dose admin-
istered by continuous intravenous infusion over days 1 to 4 [8].
Fourteen days after the completion of the etoposide infusion,
patients began to receive granulocyte–colony stimulating factor
administered by subcutaneous injection at a dose of 10 g /kg/d
until pheresis was completed. Apheresis was initiated on the
recovery of the white blood cell count to 5000/L and con-
tinued until a goal of 2  10e6 CD34 cells/kg were col-
lected. An additional amount of at least 1  10e6 CD34
cells/kg were collected as unpurged, backup PBPCs.
Mononuclear cell fractions were collected by density-gradi-
ent on the CS3000 cell separator. The cells were transferred
to a 1000-mL transfer pack, and were diluted to a density of 2
10e7 cells/mL in 20% autologous plasma. The incubation he-
matocrit was 2% in the ﬁnal incubation mixture. The transfer
bags were placed into a 37°C water bath, and the cells were
allowed to equilibrate.
While warming, the calculated amount of 4HC (MGA
Pharma, Bloomington, MN) was weighed out and transferred
into 10 mL of incubation media. The dissolved 4HC was sterile
ﬁltered into a new 15-mL conical tube using a .22-mm ﬁlter and
syringe. In a new syringe, the 4HC was drawn and injected
aseptically into the incubating cell mixture. The cell and 4HC
solution were mixed every 5 minutes for 30 minutes, and, at the
30-minute mark, the cells were washed and refrigerated until
time of infusion.
High-Dose Therapy
Patients diagnosed with AML received busulfan at 1 mg/kg
by mouth every 6 hours for 16 doses over the course of days -7
to -4 (day of infusion of stem cells being day 0). At day -3, a
single dose of etoposide was administered at 60 mg/kg. All
chemotherapy was given using adjusted ideal body weight and
adjusted body surface area. On day 0, granulocyte–colony stim-
ulating factor was initiated at 5 g/kg/d subcutaneously until
ANC was 2500/L for 3 days or 10,000/L for 1 day. The 1
patient in this trial with CML received cyclophosphamide of 60
mg/kg on days -3 and -2 in lieu of etoposide. All patients
received veno-occlusive disease prophylaxis with heparin at 100
U/kg/d continuous infusion from the ﬁrst day of the preparative
regimen through the time of engraftment. Time to hematopoi-
etic engraftment was determined to be the number of days from
the ﬁrst day ANC was 500/L until the recovery of ANC
500/L and platelets 20,000/L. Primary graft failure was
deﬁned as the absence of establishment of adequate hematopoi-
esis by day 18, whereas the bone marrow cellularity was5% or
peripheral ANC500/L, with no evidence of leukemic re-
lapse. Secondary graft failure was deﬁned as loss of engraftment
(as deﬁned by documented bone marrow cellularity 5% or
peripheral ANC 500/L) with severe neutropenia (ANC
500/L for 3 days) and marrow aplasia (bone marrow cellu-
larity5%), without improvement either spontaneously or with
growth factor support. In the case of either primary or second-
ary graft failure, the patient was re-infused with backup non-
4HC-purged autologous PBPCs of a quantity 1  10e6
CD34 cells/kg.
Dose Escalation Schema and Patient Evaluation
Dose-limiting toxicity (DLT) for this study was deﬁned as
death from the procedure or the time for ANC recovery to
500 cells/L or platelets to 20,000/L beyond 18 days.
Cohorts were initially accrued using a phase I 33 model with
escalation based on occurrence of DLT in less than one third of
patients in a cohort. If greater than one third of the patients in
a cohort experienced a DLT, then the MTD would be the dose
immediately below this point. At the point the MTD was de-
termined, the trial was expanded to treat more patients at that
dose to better estimate the time to recover, the toxicities en-
countered, and the long-term response.
Patients remained on study until time of death and were
observed for toxicity, duration of remission, relapse, and sur-
vival. Disease-free survival (DFS) is measured from day 0 to
relapse or death from disease as all patients began therapy in
remission for this trial. Overall survival is measured from day 0
to date of death from any cause. All follow-up is current to date
of manuscript submission. Toxicity was monitored in each pa-
tient following National Cancer Institute version 2.0 criteria. A
Kaplan-Meier test was used to plot DFS and overall survival. A
comparison of PBPC versus marrow blast cell sensitivity of
apoptosis induced by 4HC was performed in 4 patients who had
70% blasts in the blood and 90% in the marrow. Either the
adenosine triphosphate assay (ATPLite-M, Packard Instrument
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Company, Meriden, CT) or (CellTiter 96 AQueous assay (Pro-
mega, Madison, WI) (MTS assay) or both was used following
the manufacturers’ instructions.
RESULTS
Patient Characteristics
Fifteen patients were evaluated for this trial with only 10
enrolled because of unavailability of 4HC for the other 5. Five
men and ﬁve women, 9 Caucasians and 1 African American,
were treated from April 10, 1997 through June 1, 2002. The
median age of the enrolled patients was 45 years (range, 27 to 61
years). Nine patients had AML in second complete remission
and 1 patient was in chronic stable phase of CML. The median
duration of ﬁrst remission for those with acute leukemia was 11
months (range, 1 to 30 months). A total of 9 of these patients
were purged using 20 g/mL, whereas 1 patient had PBPCs
purged with 40 g/mL of 4HC. All patients had at least 2 
10e6 CD34 cells collected prior to purging (Table 1).
Hematopoietic Recovery
Candidates for autologous transplantation purged with
4HC were initially treated with a dosage of 40 g/mL . The ﬁrst
evaluable patient at this dose was eligible by all criteria and had
the required cell doses collected (14.5  10e6 CD34/kg col-
lected and 7.48  10e6 infused after purging). This patient
failed to engraft and subsequently died from infection (Table 2).
Given the severity of toxicity in this ﬁrst patient, the trial was
amended and the dosage of 4HC used was de-escalated to 20
g/mL for the subsequent patients and a new cohort initiated.
At this dose, only 2 of the ﬁrst 6 experienced DLT based on
delayed hematopoietic recovery and, therefore, this dose was
chosen as the MTD. The trial was continued with institutional
review board approval to allow increased accrual in this cohort
to better estimate the recovery time and evaluate the toxicities
encountered. Nine patients in total were treated at this dose (20
g/mL ) with PBPC doses and time to hematopoietic recovery
noted in Table 1. The mean number of days to recover to ANC
500/L was 17.5 (95% CI, 9.8 to 25.2), median 13 (95% CI,
11 to 15). The mean number of days to platelet recovery to
20,000/L was 27.6 (95% CI, 12.5 to 42.9), median of 18
(95% CI, 16 to 20). The mean number of days to platelet
recovery to 100,000/L was 256.9 (95% CI, -55.1 to 568.91),
median of 64 (95% CI, 63 to 66). One patient failed to recover
platelets 100,000/L. Table 2 presents results of the colony-
forming unit (CFU) assays for 9 evaluable patients. Results are
Table 1. Mean, Median, and Ranges of Days to Cell Recovery after Re-Infusion in Patients Purged with 20 g/mL of 4HC
Patient No. ANC > 500 WBC > 1
Platelets
> 20000
Platelets
> 100000
CD34/kg  10e6
Infused (pre freeze)
Total
Nucleated
Cells/kg  10e8
1 11 11 9 73 15.1 4.4
2 18 19 37 40 9.9 7.5
3 10 11 55 * 7.6 11.1
4 32 32 63 924 6.9 7.6
5 11 11 11 28 6.3 7.8
6 37 39 26 792 4.4 7.3
7 12 12 16 49 19.7 11.1
8 14 14 14 94 3.1 15.7
9 13 14 18 55 4.6 7.3
Mean (95% CI) 17.5 (9.8, 25.2) 18.1 (10.2, 26.1) 27.6 (12.5, 42.9) 253 (53, 560) 8.6 (4.4, 12) 8.9 (6.3, 11.0)
Median (95% CI) 13 (11, 15) 14 (12, 16) 18 (16, 20) 64 (303, 431) 6.9 (3.9, 9.9) 7.6 (4.2, 11.0)
Range (11-37) (11-39) (9-63) (28-924) (3.1-19.7) (4.4-15.7)
*One patient failed to recover platelets  100000 and was removed from the results of that particular statistical analysis.
WBC indicates white blood cell.
Table 2. CFUs before and after Purging and Days to Recovery in Patients Purged with 20 g/mL of 4HC
Patient No.
Before 4HC Purging X
10e5
After 4HC Purging X
10e5
ANC >
500
WBC >
1
Platelets >
20000
CFU-
GM
CFU-
GEMM
CFU-
GM
CFU-
GEMM
1 — — — — 11 11 9
2 15 5 0 0 18 19 37
3 280 20 350 20 10 11 55
4 310 20 275 25 32 32 63
5 — — — — 11 11 11
6 330 3 0 0 37 39 26
7 270 30 160 15 12 12 16
8 155 5 235 10 14 14 14
9 160 0 290 10 13 14 18
10(40g) 110 0 0 0 NA NA NA
WBC indicates white blood cell; NA, not achieved.
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varied, with the 1 patient purged using 40 g having no mea-
sured GFU-GMs or GEMMs following the purge. She also did
not have engraftment, although she did not recover with un-
purged backup infusion either. In those purged using 20 g, 3 of
7 evaluable patients had no measurable CFU-GMs following
purging, however, 4 others had a relative maintenance of CFUs
(some patients have a higher value noted after purge because of
the vagaries of the test, not because of a real increase).
Toxicity
This therapy was associated with the anticipated toxicities of
high-dose therapy. All 9 patients treated with 20 g/mL of 4HC
were diagnosed with some form of grade 3 or higher non-
hematologic toxicity. As summarized in Table 3, every patient
experienced stomatitis or mucositis and 1 patient was diagnosed
with grade 4 mucositis. Patients generally experienced the onset
of mucositis within 7 to 10 days of re-infusion, and it resolved
within 4 weeks in most patients. Other common sites of toxicity
included the skin, with sloughing or painful rash noted in 2
patients. In those patients with PBPCs purged with 40 g/mL of
4HC, signiﬁcantly delayed engraftment was the most endanger-
ing toxicity encountered.
Survival
The median follow-up of surviving patients is 2.25 years
(range, 1 to 4 years). Survival of the patients receiving PBPCs
purged with 20 g/mL of 4HC remains encouraging in this
phase I study. Five of 9 patients have survived in continuous
remission with a 3-year actuarial DFS rate of 44% and an overall
survival rate of 89%. (Figure 1).
In Vitro Cytotoxicity
In an effort to provide preliminary information concerning
the different tolerance in terms of recovery times of purging
peripheral blood compared with marrow, we performed in vitro
cytotoxicity analyses of 4 patients with a great majority of blast
cells in their mononuclear fractions (70%) (Table 4). One
patient had both the ATP assay and the less sensitive MTS assay
run on the same samples (patient A) and we noted equivalent
blood and marrow mononuclear cell sensitivity. Results are
mixed between patients, with patient B having less sensitive
marrow than blood for IC50 (requiring a higher drug concen-
tration to reach 50% cell toxicity) compared with patients A, C,
and D, who have equivalent outcomes at IC50. In contrast to
this, at the IC90 level, patient A’s marrow is more sensitive than
peripheral blood where the IC90 was not even achieved (using
the ATP assay results), but results for patient D are equivalent
for both marrow and blood, whereas those for patient C suggest
the marrow cells are more resistant than peripheral blood in this
part of the dose toxicity curve. Results from the ATP cytotox-
icity assay of apoptosis in 1 patient’s simultaneously collected
marrow and blood samples that were primarily blast cells
(90% in both samples) presents this point graphically. At
lower concentrations of 4HC, marrow is slightly more sensitive
than blood, yet at higher concentrations the inverse is true
(Figure 2). Indeed, the IC90 of blood was determined to be 1.68
m, whereas marrow was 6.86 m. The IC20 results likewise
show a great variability between patients. Within patient vari-
ability is evident here as the patient’s IC50 blood and marrow
sensitivities were similar and at IC20 the blood was less rather
than more sensitive. These results in this small group are not
conclusive, but suggest signiﬁcant intra-patient and inter-pa-
tient variability in mononuclear cell sensitivity to 4HC.
DISCUSSION
Although recent advances have improved the 5-year survival
rate in AML to approximately 30% [10,11] for patients treated
while in second or greater remission, options to prevent relapse
remain limited. Given the more advanced age of most patients
diagnosed with AML and the risks associated with high-dose
chemotherapy and allogeneic bone marrow transplantation,
these types of treatments are generally not viable forms of
therapy for the majority of patients. ABMT avoids some of the
toxicity associated with allogeneic therapy. ABMT can induce
long-term remission in some patients, whereas recent studies
indicate a treatment mortality rate of less than 5% [12]. Relapse
Figure 1. Kaplan-Meier estimate of DFS and overall survival of patients
receiving 4HC purged autologous hematopoietic stem cell transplanta-
tion.
Table 3. Toxicity Found in Patients Treated with 20 g/mL of 4HC
(n  9)
Toxicity With Without
Mean Duration
of Toxicity
(Range)
Stomatitis/mucositis
Grade 3 8 1 14.8 d (8-25)
Grade 4 1 8
Skin
Grade 3 2 7 24.5 d (14-35)
Grade 4 0 9
Delayed engraftment
ANC > 500 2 7 NA
Platelet > 20 4 5
Stomatitis/mucositis grade 3 requires intravenous hydration; grade 4
requires enteral or parenteral support.
Skin grade 3 is deﬁned as rash/sloughing on 50% of the body; grade
4 is 50%.
NA indicates not applicable.
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remains a chief concern [3]. Improvement in remission duration
may involve effective purging of the re-infused stem cells.
Phase I dose escalations have shown that 60 g/mL to 100
g/mL of 4HC can be safely used in ABMT in harvested bone
marrow and suggest improved remission duration and overall
survival [5,7,13]. However, in our study of purging PBPCs, we
were unable to escalate from 20 g/mL of 4HC, using our
deﬁnition of DLT. Indeed, the 1 patient treated at the higher
dose who had a large cell collection prior to purging was noted
to have graft failure. At our center, we feel that a time span of 18
days for the recovery of ANC or platelets is the maximum safe
delay in recovery in the autologous setting and, therefore, we did
not escalate 20 g/mL dose for this study. Whereas 2 patients
purged with 4HC at 20 g/mL experienced toxicity to the skin,
mucositis/stomatitis continued to be the predominant non-he-
matologic problem. Every patient experienced a grade 3 or
higher case of mucositis/stomatitis and required pain medica-
tion. However, all patients recovered from non-hematologic
toxicities within an average of 12 days (range, 2 to 35 days). No
cases of severe nausea, vomiting, sepsis, or diarrhea were found.
It should be noted that other reports deﬁne delayed engraftment
differently [6], which may affect the recommended dose in
future trials. Alternatively, it may be that PBPCs are more
sensitive to 4HC than bone marrow cells and, as a consequence,
cannot be exposed to equivalent dosages of 4HC. This is sug-
gested by Geiler et al. [14]. Our results note that CFUs, as
opposed to CD34 cell dose, are not reliably predictable for
engraftment, with variable results noted in our study and no
clear association with recovery times. This is similar to prior
reports in which it has been shown that even patients with 1%
recovery of CFUs using purged marrow engraft, although re-
covery times are delayed [14,15].
Despite the lower dosage of 4HC used in this study, 5 of 9
(56%) patients remain disease-free since autologous transplan-
tation with a median follow-up of 2.25 years. The median
duration of ﬁrst remission was only 11 months in this group.
Our results in this small group also compare favorably with the
25% DFS rate using unpurged, autologous marrow for patients
in remission with acute leukemia [16]. Our results compare
favorably with the 32% 3-year DFS rate using bone marrow
purged with 4HC, despite the much higher dose of 4HC toler-
ated to purge marrow as well [6]. This is similar to our experi-
ence with patients considered for this trial but not enrolled
because of lack of 4HC availability. These 5 were otherwise
treated in an identical manner as those on trial who received
purged cells and 4 of 5 relapsed and died within 4 months of
therapy, with only 1 remaining in remission. Prior reports sug-
gest a low CFU percentage after purging of marrow would
indicate an elimination of a signiﬁcant number of committed
precursors to a level that should relate to a similar decrease in
leukemic progenitors [14]. Our results suggest that recovery of
CFUs from purging peripheral blood does not appear to relate
to long-term remission, with 3 of the 4 evaluable patients main-
taining remission having a signiﬁcant percentage of recovery of
CFU-GM. The use of peripheral blood rather than marrow may
result in a much larger pool of stem cells than with marrow,
therefore, the residual percentages following purging may not
correlate in the same manner as marrow for time to recover or
efﬁcacy of the purge process.
The potential for differential sensitivity of peripheral blood
blasts compared with marrow blasts as suggested, although not
conﬁrmed, by Table 4 and Figure 2, may explain why a lower
dose of 4HC purging of peripheral blood may still be very
effective for some patients. Our preliminary analysis in a few
patients suggests that the relative 4HC sensitivity of mononu-
clear cells in the marrow and blood may vary not only between
patients, but also within patients at different points on the dose
toxicity curve. Larger studies purifying the blast cells in the
marrow and blood and using more than 1 assay of apoptosis
would be needed to investigate this hypothesis in more detail. In
vitro purging even with the lower doses used in this trial actually
equate to a very high dose of drug exposure (66 mol/L) com-
pared with the exposure levels encountered with in vivo cyclo-
phosphamide therapy. This perspective allows us to better un-
Figure 2. Cytotoxicity of 4HC on isolated mononuclear cells by ATP
assay of 1 patient’s mononuclear cells (primarily blasts) isolated from
blood and marrow simultaneously and treated with 4-HC.
Table 4. Cytotoxicity of 4HC on Isolated Mononuclear Cells by ATP Assay and MTS Assay
Patient Assay
IC 20 IC 50 IC 90
Blood Marrow Blood Marrow Blood Marrow
A MTS 9.05 8.95 23.92 21.06 NA NA
MTS .54 — 1.10 — — —
ATP .51 <.78 1.08 <.78 NA .40
B MTS 1.3 .85 3.07 1.63 NA NA
C ATP .22 .10 .38 .36 1.68 6.86
D ATP .10 .08 .15 .16 .26 .34
NA indicates level not achieved at concentrations used.
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derstand the signiﬁcant purging effect noted on collected versus
infused cell counts and the delay in hematopoietic recovery
noted using even these lower doses for purging of peripheral
blood.
Effective purging of autologous grafts may allow for ex-
tended remissions. This phase I study estimates the MTD of
4HC to be used to purge peripheral blood stem cells as 20 g.
Although mucositis and gastrointestinal complaints are com-
mon, they resolved following hematopoietic count recovery in
all patients treated at this dose. Despite the relatively low dose of
4HC, our clinical results are favorable and suggest that contin-
ued study of in vitro purging may be helpful. Studies aimed at
investigating whether blast cells in the blood have different
sensitivities than those found in the marrow, as our anecdotal
evidence above suggests may occur in some patients, may be a
fruitful effort to exploit cell differences. In the future, the po-
tential beneﬁts of adding amifostine prior to purging to protect
the stem cells from the 4HC effect may be beneﬁcial. This may
allow further escalation of 4HC and, subsequently, a greater
decrease in the number of viable leukemia cells present in grafts.
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